"Insulysin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme the catalyzes the degradation of insulin, glucagon and other polypeptides. It is inhibited by bacitracin, chelating agents EDTA and 1,10-phenanthroline, and by thiol-blocking reagents such as N-ethylmaleimide, but not phosphoramidon. (Eur J Biochem 1994;223:1-5) EC 3.4.24.56.
Descriptor ID |
D007339
|
MeSH Number(s) |
D08.811.277.656.300.480.300 D08.811.277.656.675.374.300
|
Concept/Terms |
Insulysin- Insulysin
- Insulin-Degrading Enzyme
- Enzyme, Insulin-Degrading
- Insulin Degrading Enzyme
- Insulin Protease
- Protease, Insulin
- Insulin Proteinase
- Proteinase, Insulin
- Insulinase
|
Below are MeSH descriptors whose meaning is more general than "Insulysin".
Below are MeSH descriptors whose meaning is more specific than "Insulysin".
This graph shows the total number of publications written about "Insulysin" by people in this website by year, and whether "Insulysin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1997 | 2 | 0 | 2 |
1998 | 1 | 0 | 1 |
2000 | 3 | 0 | 3 |
2005 | 1 | 0 | 1 |
2006 | 2 | 0 | 2 |
2007 | 3 | 0 | 3 |
2008 | 4 | 0 | 4 |
2009 | 5 | 0 | 5 |
2010 | 4 | 0 | 4 |
2011 | 0 | 1 | 1 |
2013 | 1 | 0 | 1 |
2014 | 3 | 0 | 3 |
2015 | 2 | 1 | 3 |
2018 | 2 | 0 | 2 |
2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Insulysin" by people in Profiles.
-
Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. Eur J Med Chem. 2019 Oct 01; 179:557-566.
-
Catalytic Mechanism of Amyloid-ß Peptide Degradation by Insulin Degrading Enzyme: Insights from Quantum Mechanics and Molecular Mechanics Style Møller-Plesset Second Order Perturbation Theory Calculation. J Chem Inf Model. 2018 09 24; 58(9):1926-1934.
-
Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme. Elife. 2018 03 29; 7.
-
Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus. Trends Endocrinol Metab. 2016 Jan; 27(1):24-34.
-
Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice. Nat Commun. 2015 Sep 23; 6:8250.
-
Structures of human CCL18, CCL3, and CCL4 reveal molecular determinants for quaternary structures and sensitivity to insulin-degrading enzyme. J Mol Biol. 2015 Mar 27; 427(6 Pt B):1345-1358.
-
Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme. Eur J Med Chem. 2015 Jan 27; 90:547-67.
-
Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014 Jul 03; 511(7507):94-8.
-
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis. Eur J Med Chem. 2014 May 22; 79:184-93.
-
Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme. Proc Natl Acad Sci U S A. 2013 Aug 20; 110(34):13827-32.